Embla Bodén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Embla Bodén has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Lindstedt
Department of Clinical Sciences, Lund University, Lund, Sweden
5 shared publications - Gabriel Hirdman
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
3 shared publications Anna Niroomand
Department of Clinical Sciences, Lund University, 22184 Lund, Sweden
2 shared publications- Franziska Olm
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
2 shared publications Alessandra Mularoni
Unit of Infectious Diseases and Infection Control, ISMETT-IRCCS (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione-Istituto di Ricovero e Cura a Carattere Scientifico), Palermo, Italy
1 shared publicationAlim Hirji
Department of Medicine, University of Alberta, Edmonton, AB, Canada
1 shared publication
Latest Publications
- Open Access
- 8 July 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (9) , 101352
Non-Aspergillus fumigatus mould infections in lung transplant recipients: an international, multicentre, case–control study
- 8 July 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (9) , 101352
Open AccessNon-Aspergillus fumigatus mould infections in lung transplant recipients: an international, multicentre, case–control study
- Open Access
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 448-459
Xenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 448-459
Open AccessXenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion
- Open Access
A Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer
Lung cancer represents the leading cause of annual cancer-related deaths worldwide, accounting for 12.9%. The available treatment options for patients who experience disease progression remain limited. Targeted therapeutic approaches are promising but further understanding of the role of genetic alterations in tumorigenesis is imperative. The MET gene has garnered great interest in this regard. The aim of this systematic review was to analyze the findings from multiple studies to provide a comprehensive and unbiased summary of the evidence. A systematic search was conducted in the reputable scientific databases Embase and PubMed, leading to the inclusion of twenty-two articles, following the PRISMA guidelines, elucidating the biological role of MET in lung cancer and targeted therapies. The systematic review was registered in PROSPERO with registration ID: CRD42023437714. MET mutations were detected in 7.6–11.0% of cases while MET gene amplification was observed in 3.9–22.0%. Six studies showed favorable treatment outcomes utilizing MET inhibitors compared to standard treatment or placebo, with increases in PFS and OS ranging from 0.9 to 12.4 and 7.2 to 24.2 months, respectively, and one study reporting an increase in ORR by 17.3%. Furthermore, patients with a higher mutational burden may derive greater benefit from treatment with MET tyrosine kinase inhibitors (TKIs) than those with a lower mutational burden. Conversely, two studies reported no beneficial effect from adjunctive treatment with a MET targeted therapy. Given these findings, there is an urgent need to identify effective therapeutic strategies specifically targeting the MET gene in lung cancer patients.
Open AccessA Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer
Lung cancer represents the leading cause of annual cancer-related deaths worldwide, accounting for 12.9%. The available treatment options for patients who experience disease progression remain limited. Targeted therapeutic approaches are promising but further understanding of the role of genetic alterations in tumorigenesis is imperative. The MET gene has garnered great interest in this regard. The aim of this systematic review was to analyze the findings from multiple studies to provide a comprehensive and unbiased summary of the evidence. A systematic search was conducted in the reputable scientific databases Embase and PubMed, leading to the inclusion of twenty-two articles, following the PRISMA guidelines, elucidating the biological role of MET in lung cancer and targeted therapies. The systematic review was registered in PROSPERO with registration ID: CRD42023437714. MET mutations were detected in 7.6–11.0% of cases while MET gene amplification was observed in 3.9–22.0%. Six studies showed favorable treatment outcomes utilizing MET inhibitors compared to standard treatment or placebo, with increases in PFS and OS ranging from 0.9 to 12.4 and 7.2 to 24.2 months, respectively, and one study reporting an increase in ORR by 17.3%. Furthermore, patients with a higher mutational burden may derive greater benefit from treatment with MET tyrosine kinase inhibitors (TKIs) than those with a lower mutational burden. Conversely, two studies reported no beneficial effect from adjunctive treatment with a MET targeted therapy. Given these findings, there is an urgent need to identify effective therapeutic strategies specifically targeting the MET gene in lung cancer patients.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4370
Quantitative Proteomics in Exhaled Breath for Characterization and Diagnosis of COVID-19
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4370
Quantitative Proteomics in Exhaled Breath for Characterization and Diagnosis of COVID-19
- Open Access
- 28 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2738
Quantitative Proteomics Indicate Radical Removal of Non-Small Cell Lung Cancer and Predict Outcome
Non-small cell lung cancer (NSCLC) is associated with low survival rates, often due to late diagnosis and lack of personalized medicine. Diagnosing and monitoring NSCLC using blood samples has lately gained interest due to its less invasive nature. In the present study, plasma was collected at three timepoints and analyzed using proximity extension assay technology and quantitative real-time polymerase chain reaction in patients with primary NSCLC stages IA–IIIA undergoing surgery. Results were adjusted for patient demographics, tumor, node, metastasis (TNM) stage, and multiple testing. Major histocompatibility (MHC) class 1 polypeptide-related sequence A/B (MIC-A/B) and tumor necrosis factor ligand superfamily member 6 (FASLG) were significantly increased post-surgery, suggesting radical removal of cancerous cells. Levels of hepatocyte growth factor (HGF) initially increased postoperatively but were later lowered, potentially indicating radical removal of malignant cells. The levels of FASLG in patients who later died or had a relapse of NSCLC were lower at all three timepoints compared to surviving patients without relapse, indicating that FASLG may be used as a prognostic biomarker. The biomarkers were confirmed using microarray data. In conclusion, quantitative proteomics could be used for NSCLC identification but may also provide information on radical surgical removal of NSCLC and post-surgical prognosis.
- 28 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (11) , 2738
Open AccessQuantitative Proteomics Indicate Radical Removal of Non-Small Cell Lung Cancer and Predict Outcome
Non-small cell lung cancer (NSCLC) is associated with low survival rates, often due to late diagnosis and lack of personalized medicine. Diagnosing and monitoring NSCLC using blood samples has lately gained interest due to its less invasive nature. In the present study, plasma was collected at three timepoints and analyzed using proximity extension assay technology and quantitative real-time polymerase chain reaction in patients with primary NSCLC stages IA–IIIA undergoing surgery. Results were adjusted for patient demographics, tumor, node, metastasis (TNM) stage, and multiple testing. Major histocompatibility (MHC) class 1 polypeptide-related sequence A/B (MIC-A/B) and tumor necrosis factor ligand superfamily member 6 (FASLG) were significantly increased post-surgery, suggesting radical removal of cancerous cells. Levels of hepatocyte growth factor (HGF) initially increased postoperatively but were later lowered, potentially indicating radical removal of malignant cells. The levels of FASLG in patients who later died or had a relapse of NSCLC were lower at all three timepoints compared to surviving patients without relapse, indicating that FASLG may be used as a prognostic biomarker. The biomarkers were confirmed using microarray data. In conclusion, quantitative proteomics could be used for NSCLC identification but may also provide information on radical surgical removal of NSCLC and post-surgical prognosis.